Olema Pharmaceuticals (OLMA) Cash from Operations (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Cash from Operations of 45987000.0 for Q1 2026, down 4.57% year-over-year from 48187135.71 in Q1 2025, and down 19.99% quarter-over-quarter from 38327000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Cash from Operations (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Cash from Operations data on file, last reported at 45987000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 45987000.0, down 4.57% year-over-year; the trailing twelve-month figure through Mar 2026 was 148724000.0 (down 19.14% YoY), and the FY2025 annual result was 146716000.0, down 40.6% from the prior year.
- Cash from Operations fell to 45987000.0 in Q1 2026 per OLMA's latest filing, from 38327000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 17903000.0 in Q1 2022 and troughed at 45987000.0 in Q1 2026.
- A 5-year average of 27226235.29 and a median of 26284000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 197.13% in 2022, then increased 16.41% in 2023.
- A 5-year view of Cash from Operations shows it stood at 19711000.0 in 2022, then grew by 6.27% to 18476000.0 in 2023, then slumped by 42.26% to 26284000.0 in 2024, then sank by 45.82% to 38327000.0 in 2025, then retreated by 19.99% to 45987000.0 in 2026.
- Business Quant data shows OLMA's Cash from Operations at 45987000.0 in Q1 2026, 38327000.0 in Q4 2025, and 34527000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | -45.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.99 Mn |
| Mar 31, 2026 | -45.99 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Mar 31, 2024 | -23.50 Mn |
| Mar 31, 2024 | -23.50 Mn |
| Dec 31, 2023 | -18.48 Mn |
| Dec 31, 2023 | -18.48 Mn |